⏱ 4 min read
Bone tissue is metabolically far more dynamic than popular intuition suggests: it is continuously remodeled throughout life through the balance between osteoblasts (bone-forming cells) and osteoclasts (resorbing cells); the balance between formation and resorption determines bone mineral density, which increases until age 25-30 (peak bone mass), is maintained for 1-2 decades, and declines progressively from the fifth decade of life; in women, the drop in estrogen at menopause dramatically accelerates loss during the first 5-10 postmenopausal years. Osteoporosis is the clinical condition of low bone mass and deteriorated microarchitecture with increased risk of fragility fracture, one of the leading causes of morbidity, dependence, and mortality in older adults.
Adequate calcium intake is necessary for bone mineralization, but modern clinical data have considerably qualified the simplification of "more calcium = better bone":
Reasonable current clinical practice: prioritize dietary calcium intake, reserve supplements for people with a documented dietary deficit or established osteoporosis, always combine with vitamin D, and consider K2 when high doses are used.
Vitamin D regulates intestinal calcium absorption and bone mineralization; subclinical deficiencies are extremely common at high latitudes or in people with little sun exposure; clinically significant deficiency is associated with osteomalacia, bone pain, proximal muscle weakness, and increased fracture risk. Supplementation with 1000-2000 IU/day corrects subclinical deficiencies in most people.
Vitamin K2 (MK-7) activates osteocalcin (the bone Gla protein), which captures calcium and deposits it in the bone matrix; without adequate K2, osteocalcin remains inactive and calcium absorbed via vitamin D may be misdirected to vascular tissues instead of bone. The D3+K2 synergy is one of the strongest arguments for combining these two vitamins in supplementation specifically aimed at bone health.
The most effective stimulus for maintaining and increasing bone density is mechanical exercise with significant loading: walking is better than a sedentary lifestyle but clearly insufficient for bone; running provides impact that stimulates osteoblasts; jumping (rope, plyometrics) has a significant bone effect; but the most cost-effective intervention for bone is progressive strength training with significant resistance (60-85% of 1RM, 8-12 repetitions, 2-3 sessions per week, sustained progression).
The Australian LIFTMOR trial (2018) demonstrated significant improvements in bone density in postmenopausal women with osteopenia/osteoporosis after 8 months of supervised high-intensity strength training (squats, deadlifts, presses), with an excellent safety profile. This intervention is comparable or superior in magnitude to some pharmacological interventions and has additional benefits on muscle mass, balance, and fall prevention (the leading cause of hip fracture in older adults).
In established osteoporosis (T-score ≤ -2.5), a history of fragility fracture, or a major fracture risk above 20% at 10 years (FRAX), first-line treatment is bisphosphonates (alendronate, risedronate, zoledronic acid) because of their documented efficacy in reducing vertebral, nonvertebral, and hip fractures; denosumab, teriparatide, or romosozumab are alternatives depending on the context. Nutritional and exercise interventions are complementary but not substitutes in these cases.
Long-term bone health is a decades-long project that combines: adequate nutritional intake of calcium (preferably from food), sufficient vitamin D, K2 when appropriate, adequate protein, and especially progressive strength training from an early age; in established osteoporosis, specific pharmacological intervention is necessary, complemented by the other measures; miraculous "solutions" via isolated supplements do not exist.
Information, not medical advice.